Researchers at the Hebrew University of Jerusalem conducted a study showing that cannabidiol (CBD) and cannabigerol (CBG), two non-psychoactive cannabis compounds, may help treat metabolic dysfunction-associated steatotic liver disease (MASLD).
Study: CBD and CBG Show Potential in Treating Fatty Liver Disease